search

Active clinical trials for "Carcinoma, Merkel Cell"

Results 91-100 of 117

S9716: Combination Chemotherapy in Treating Patients With Merkel Cell Cancer

Neuroendocrine Carcinoma of the Skin

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining cyclophosphamide, methotrexate, and fluorouracil in treating patients with Merkel cell cancer.

Completed3 enrollment criteria

FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced...

Advanced Solid TumorsLymphoma16 more

FT500 is an off-the-shelf, iPSC-derived NK cell product that can bridge innate and adaptive immunity, and has the potential to overcome multiple mechanisms of immune checkpoint inhibitor (ICI) resistance. The preclinical data provide compelling evidence supporting the clinical investigation of FT500 as monotherapy and in combination with ICI in participants with advanced solid tumors.

Completed25 enrollment criteria

A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With...

Non-small Cell Lung CancerSquamous Cell Carcinoma of the Head and Neck10 more

This is a Phase 1, open-label, dose-escalation and dose-expansion study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD) and clinical activity of etrumadenant (AB928) in combination with zimberelimab (AB122) (an anti-PD-1 antibody) in participants with advanced malignancies.

Completed20 enrollment criteria

A Proof-of-Concept Trial of GLA-SE in Patients With Merkel Cell Carcinoma

Merkel Cell Carcinoma

This is a single arm, open-label, single center study evaluating the safety, feasibility, clinical efficacy and immunogenicity of GLA-SE administration to patients with Merkel cell carcinoma. Ten patients will be treated. The goal is for GLA-SE to assist the patient's own immune system in attacking the cancer cells.

Completed18 enrollment criteria

Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid...

Extensive Stage Small Cell Lung CancerHereditary Paraganglioma46 more

RATIONALE: Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as vinorelbine ditartrate, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving temsirolimus together with vinorelbine ditartrate may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of giving temsirolimus and vinorelbine ditartrate together in treating patients with unresectable or metastatic solid tumors.

Completed28 enrollment criteria

S0331: Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer...

Recurrent Neuroendocrine Carcinoma of the SkinStage II Neuroendocrine Carcinoma of the Skin1 more

This phase II trial is studying how well imatinib mesylate works in treating patients with metastatic or unresectable Merkel cell cancer. Imatinib mesylate may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth

Completed26 enrollment criteria

BB-10901 in Treating Patients With Relapsed or Refractory Solid Tumors

Ovarian CancerMerkel Cell Carcinoma1 more

RATIONALE: Monoclonal antibodies, such as BB-10901, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. PURPOSE: This phase I trial is studying the side effects and best dose of BB-10901 in treating patients with relapsed or refractory solid tumors.

Completed60 enrollment criteria

T-VEC in Non-melanoma Skin Cancer

Non-melanoma Skin CancerBasal Cell Carcinoma3 more

Evaluation of the mechanism of Action of talimogene laherparepvec (T-VEC) in patients with locally advanced non-melanoma skin cancer.

Completed13 enrollment criteria

Study To Evaluate The Safety, Tolerability And Immunogenicity Of 4 mg Of ITI-3000 In Patients With...

Merkel Cell Carcinoma

This Phase I clinical trial will evaluate the safety, tolerability, and immunogenicity of 4 mg doses of ITI-3000 in participants with polyomavirus-positive Merkel cell carcinoma (MCC).

Completed25 enrollment criteria

A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers...

Head and Neck Squamous Cell CarcinomaBreast Cancer9 more

This is an open-label, multicenter, Phase 1/2 study of the CTLA-4 antibody, tremelimumab, and the PD-L1 antibody, durvalumab (MEDI4736), in combination with the tumor microenvironment (TME) modulator poly-ICLC, a TLR3 agonist, in subjects with advanced, measurable, biopsy-accessible cancers.

Completed24 enrollment criteria
1...9101112

Need Help? Contact our team!


We'll reach out to this number within 24 hrs